Analyst Price Target is $3.67
▲ +175.69% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Amneal Pharmaceuticals in the last 3 months. The average price target is $3.67, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 175.69% upside from the last price of $1.33.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Amneal Pharmaceuticals.
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.